DC-CIK联合化疗治疗晚期非小细胞肺癌的近期临床疗效

目的：观察DC-CIK联合化疗治疗晚期非小细胞肺癌的近期疗效及不良反应。方法：纳入62例Ⅲ～Ⅳ晚期非小细胞肺癌患者,根据随机数字表将患者随机纳入治疗组和对照组。治疗组采用DC-CIK联合NP化疗方案;对照组采用单纯NP化疗。治疗两个疗程,比较两组患者治疗前后的瘤体大小变化、免疫功能和副反应。结果：治疗组瘤体变化有效率45.16%,与对照组的32.26%比较差异无统计学意义（P〉0.05）,治疗组瘤体稳定率83.87%,明显优于对照组的61.29%（P〈0.05）;治疗组治疗后外周血T细胞亚群无明显变化（P〉0.05）,对照组患者治疗后外周血CD3＋、CD4＋细胞比例明显下降（P〈0.05）;治疗组的不良反应与单纯化疗组比较差异无统计学意义（P〉0.05）。结论：与单纯化疗相比,应用DC-CIK联合化疗治疗中晚期非小细胞肺癌近期疗效较好,可有效控制瘤体,保护和提高患者细胞免疫功能。

Immediate Clinical Effects of Administering Dendritic Cells and Cytokine Induced Killer Cells Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Objective：To investigate immediate effects and adverse reaction of administering dendritic cells（DC） and cytokine induced killer cells（CIK） combined with chemotherapy in patients with advanced non-small cell lung cancer（NSCLC）.Method：According to random number form,62 cases ofⅢ-Ⅳadvanced NSCLC patients were divided two groups randomly：treatment group and control group. The treatment group received DC-CIK combined with NP chemotherapy.The control group received only NP chemotherapy.The size of the tumor,T lymphocyte subtypes in peripheral blood and adverse reaction of the two group patients were analyzed and controlled.Result：The effect effective rate of tumor change of treatment group was 45.16%,showed no significant difference compare with 32.26% of control group.Stability rate of tumor change of treatment group was 83.87%,significant higher than 61.29% of control group（P0.05）.The levels of T lymphocyte subtypes of treatment group showed no difference after treatment（P0.05）,while the level of CD3＋、CD4＋ and CD4＋/CD8＋ decreased compare with before treatment（P0.05）.There was no difference of adverse reaction between two group.Conclusion：Compared with control group,using DC-CIK combined with chemotherapy have better immediate clinical effects.It can effective control tumor and elevate cellular immune function of patients.